高脂血症患者载脂蛋白B基因突变对阿托伐他汀调脂作用的影响

The influence of Apolipoprotein B gene mutations on the lipid-regulating effect of atorvastatin in patients with hyperlipidemia

目的探讨载脂蛋白B（ApoB）基因突变对阿托伐他汀调脂作用的影响。方法选取152例高脂血症患者为研究对象，采用聚合酶链反应一限制性内切片段长度多态性（PCR．RFLP）方法检测高脂血症患者ApoB基因多态性。所有患者给予阿托伐他汀治疗，分别在治疗前后采用酶法测定血脂水平。分析不同基因型（非x＋携带者和x＋携带者）患者的血脂水平[总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL—C）、高密度脂蛋白胆固醇（HDL—C）]。结果非x＋携带者治疗前后TC、LDL—c下降百分比分别为（28．98±5．21）％，LDL-12下降百分比为（32．67±7．19）％，均大于x＋携带者的（18．97±4．01）％、（26．07±3．45）％（均P〈0．05）。非x＋携带者治疗前后TG下降百分比和HDL—C升高百分比与x＋携带者比较差异均无统计学意义（均P〉0．05）。结论ApoB基因变异影响高脂血症患者的血清TC和LDL—C水平，X＋携带者的血脂水平较非x＋携带者高；且阿托伐他汀对X＋携带者的调脂作用较弱。

Objective To explore the influence of Apolipoprotein B（ApoB） gene mutations on the lipid-reg- ulating effect of atorvastatin in patients with hyperlipidemia. Methods 152 patients with hyperlipidemia were selected as the research targets, the ApoB gene polymorphism was detected by polymerase chain reaction-restrictive cut inside fragment length polymorphism（PCR-RFLP） method. All the patients given atorvastatin treatment,and determined lipid levels before and after treatment. Then the lipid level [ total cholesterol （TC） , triglyceride （TG）, low-density lipoprotein cholesterol （ LDL-C）, high density lipoprotein cholesterol （ HDL-C ） ] of the different genotypes （ no X ＋ carriers and X ＋ carriers） of patients were analyzed. Results The percentage decline of TC and LDL-C of no X ＋ carriers was （28. 98 ± 5.21 ）% , （32.67 ± 7. 19）% , respectively, which were higher than those of X ＋ carriers [ （ 18.97 ± 4.01 ） % and （ 26.07± 3.45 ） % ] （ P 〈 0. 05 ）. The percentage decline of TG and increasing of HDL-C of no X ＋ car- tiers had no significance difference with those of X ＋ carriers （ all P 〉 0.05 ）. Conclusion ApoB gene mutation influ- ence serum TC and LDL-C levels of hyperlipidemia patients, the levels of TC and LDL-C of X ＋ carriers are higher than those of no X ＋ carriers; And the lipid-regulating effect of atorvastatin for X ＋ carriers is more weaker.